EcoDrugPlus

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSCPOG00000013605
Gene Symbol: MAPK10
2 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSCPOG00000030297
Gene Symbol: MAPK11
4 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSCPOG00000014893
Gene Symbol: MAPK14
4 Cross references
295 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSCPOG00000003253
Gene Symbol: MAPK3
4 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSCPOG00000038234
Gene Symbol: MAPK8
4 Cross references
292 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSCPOG00000013948
Gene Symbol: MAPK9
4 Cross references
218 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSCPOG00000003053
Gene Symbol: MAP2K1
4 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSCPOG00000025428
Gene Symbol: MAP2K2
2 Cross references
272 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSCPOG00000015017
Gene Symbol: MAP3K1
2 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSCPOG00000015417
Gene Symbol: MAP3K10
2 Cross references
186 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSCPOG00000034854
Gene Symbol: MAP3K11
2 Cross references
184 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSCPOG00000000971
Gene Symbol: MAP3K12
2 Cross references
254 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).